Monopar puts a stop to its chemo com­pli­ca­tion drug; Ex­i­cure ex­plores fu­ture trans­ac­tions

The biotech Monopar Ther­a­peu­tics is putting a ki­bosh on a study for its drug to pre­vent se­vere oral mu­cosi­tis (SOM) in pa­tients who are go­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA